Tasca Therapeutics Secures New Funding to Accelerate Innovation
Tasca Therapeutics Corp. is embarking on an exciting journey in the biotechnology sector after securing $52 million through a Series A financing round. Co-led by prominent investors Regeneron Ventures and Cure Ventures, with contributions from Invus Group, this funding marks a significant milestone for Tasca as it aims to expand its groundbreaking drug discovery efforts.
Advancement of Drug Discovery Platform
The new funds will propel Tasca's unique drug discovery platform, designed to identify and map novel lipid-binding pockets on proteins. This innovative approach is expected to expedite the development of their lead program, CP-383, which is on the verge of entering Phase 1/2 clinical proof-of-concept studies. With this financing, the company is poised to broaden its pipeline, exploring additional drug candidates.
Leadership's Vision
Milenko Cicmil, co-founder and CEO of Tasca, expressed enthusiasm about this financial boost, highlighting the importance of support from leading life science investors and their innovative scientific co-founders, which include Xu Wu, Ph.D., David Fisher, M.D., Ph.D., and Duojia Pan, Ph.D. Their pioneering work has already produced CP-383, a molecule demonstrating impressive efficacy across various cancer types, laying the groundwork for its future clinical applications.
Targeting Cancer with Novel Therapeutics
Tasca's innovative research centers on the mechanism of auto-palmitoylation, a post-translational modification of proteins that brings about unique binding sites for potential therapeutics. This well-mapped approach enables the identification of druggable targets, positioning Tasca favorably in the competitive oncology landscape.
The Promise of CP-383
CP-383, Tasca’s most advanced candidate, has shown a remarkable potential in preclinical studies, evidencing its anti-cancer capabilities through both in vitro and in vivo analyses. Tasca is particularly focused on evaluating this candidate in clinical settings against small cell lung cancer, colorectal cancer, head and neck cancer, and brain cancer.
Experienced Leadership Team
Tasca boasts an executive leadership team brimming with extensive experience in drug discovery and biotechnology. Leaders within the organization have previously held key roles at industry giants such as Merck, AstraZeneca, Bristol Myers Squibb, and Novartis. Their vast knowledge in oncology and drug development positions Tasca to navigate the complexities typical of early-stage biotech ventures.
Community Support and Recognition
Praveen Tipirneni, M.D., the chairman of the board, emphasized the impressive in vivo data generated by Tasca and shared his excitement regarding Milenko's leadership and the backing from such respected firms. This confidence is echoed by other leaders in the field, including Dave Fallace from Cure Ventures, who underscores the potential Tasca has in challenging previously deemed undruggable targets.
About Tasca Therapeutics
Tasca Therapeutics is a privately held biotechnology entity concentrating on the discovery and development of small molecule inhibitors targeting auto-palmitoylated proteins that play crucial roles in cancer biology. Their lead program, CP-383, is distinct in its first-in-class designation and boasts promising preclinical results against a spectrum of cancer types. For more information, visit their website for updates as they continue to push the boundaries of therapeutic innovations.
Frequently Asked Questions
What is the primary focus of Tasca Therapeutics?
Tasca Therapeutics is dedicated to discovering and developing small molecule inhibitors that target specific proteins implicated in cancer.
What funding amount did Tasca Therapeutics recently secure?
Tasca Therapeutics has raised $52 million in a Series A financing round.
Who are the main investors in Tasca's Series A funding?
The funding was co-led by Regeneron Ventures and Cure Ventures, with participation from Invus Group.
What is the significance of the drug CP-383?
CP-383 is a first-in-class molecule showcasing strong activity against multiple cancer types, set to enter early-stage clinical trials.
How does Tasca identify its drug targets?
Tasca's innovative platform utilizes mass spectrometry-based proteomics to identify lipid-binding pockets and targets with auto-palmitoylation.
